Brains Bioceutical Corp., a Vancouver-based maker of pharmaceutical-grade cannabinoid ingredients, has agreed to go public through a merger with Armada Acquisition Corp. III at an implied pre-money equity value of about US$750m, the companies said on 5 November 2026.
Why Armada Acquisition Corp. III is buying Brains Bioceutical Corp.
Brains supplies active pharmaceutical ingredients such as CBD, THC, CBN and CBG from BSPG Laboratories' MHRA-registered facility in Kent, and is running drug programmes in glaucoma and epilepsy. Chief executive Rick Brar said becoming a listed company "will provide Brains with the capital and market visibility" to grow; Armada III chairman Stephen Herbert said "We believe Brains meets those criteria."
Deal terms and financing
Existing Brains shareholders are expected to roll 100% of their equity into the combined company. The release refers to contemplated private placement financings but does not give their size, and cash available at closing will depend on Armada III's trust balance after redemptions.
Regulatory approvals and timing
The deal requires approval from both sets of shareholders, an effective SEC registration statement, Nasdaq listing approval and other regulatory approvals. Closing is expected in the second quarter of 2027.
Market context
The transaction joins a wave of life-sciences SPAC listings in 2026. Cannabinoid medicines remain under regulatory scrutiny in the US, where the FDA has said CBD products need a new regulatory pathway.
